Could a cancer drug tame cushing disease?
NCT ID NCT03774446
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests seliciclib, an oral drug, in 13 adults with Cushing disease. The goal is to see if 4 weeks of treatment can lower high cortisol levels to normal or reduce them by at least half. Researchers will also monitor safety and check for changes in tumor size and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Seliciclib (R-roscovitine)
What this could lead to
If successful, this could point toward a new oral treatment option for Cushing disease, potentially reducing the need for surgery or long-term medication.
What could go wrong
This is a small, early-phase trial with only 13 participants, so results may not apply broadly. The drug may not effectively lower cortisol or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUSHING DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact